The Life Sciences Report

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results

Fri, 12 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/12/2026

Oculis Holding AG (OCS:NASDAQ; OCS:XICE) launches PREDICT-1, a genotype-based trial for licaminlimab, targeting 10M moderate-to-severe dry eye patients.

Global neuro-ophthalmology and ophthalmology biopharma company Oculis Holding AG (OCS:NASDAQ; OCS:XICE) announced that the first patient has been randomized in its PREDICT-1 (personalized dry eye disease investigational clinical trial) genotype-based registrational trial in dry eye disease (DED) on June 9, 2026. The company believes that its experimental medication, licaminlimab, could become a precise medical approach to treating DED.

This initial trial is designed to further evaluate the effects licaminlimab on DED and determine its level of safety "compared with vehicle in patients carrying a specific TNFR1 genotype."

TNFR1 is a key receptor mediating TNFα-driven inflammation and apoptosis, and licaminlimab seemed to show good clinical responses in patients with a specific TNFR1 genotype in Phase 2 trials. These results support the theory that genetic variation in the TNF/TNF1 pathway could account for variability in the inflammatory response, which could play a role in ocular surface pathology in DED.

According to the company, "In the U.S., approximately 10 million diagnosed patients suffer from moderate to severe DED. Current disease management relies on a trial-and-error therapeutic approach, with a minority (~13%) of patients experiencing sustained relief, leading to an 85-90% discontinuation rate within the first 6 months, underscoring the significant unmet need for a targeted, effective treatment approach."

While licaminlimab is an investigational anti-TNFα eye drop being developed with a single-chain antibody fragment technology specifically designed for the treatment of ocular inflammatory diseases, it has already shown positive treatment effects on both the signs and symptoms of DED and has been well-tolerated.

Riad Sherif, M.D., Chief Executive Officer of Oculis, remarked, "The first patient randomized in PREDICT-1 marks an important milestone for Licaminlimab and for the advancement of a genotype-based, precision medicine approach in dry eye disease, a highly unsatisfied market. Supported by a well-validated anti-TNFα mechanism of action, this targeted trial is designed to maximize clinical efficiency by focusing on patients most likely to respond. We believe Licaminlimab, if approved, has the potential to reshape the treatment paradigm for this multifactorial disease. By pioneering an innovative development strategy, our objective is to deliver a precision medicine approach that addresses a major unmet need for the millions of underserved patients currently constrained by a trial-and-error method."

Anat Galor, M.D., M.S.P.H., Professor of Ophthalmology, Bascom Palmer Eye Institute, Miami, added: "The advancement of Licaminlimab represents a meaningful progress in dry eye disease research, particularly in light of the substantial unmet need among patients and clinicians, many of whom remain dissatisfied and frustrated with the current 'trial-and-error' treatment paradigm. Results from prior Phase 2 studies demonstrated clinically relevant improvements in both signs and symptoms, with a more pronounced and differentiated response observed in patients carrying a specific TNFR1 genotype. If confirmed in the PREDICT-1 study, this genotype-informed, precision medicine approach has the potential to enable a more targeted treatment strategy for this highly heterogeneous patient population, where a significant unmet medical need persists."

Pharma Sector R&D Underfunded

DED is a common multifactorial disease estimated to impact more than 110 million people in the U.S., UK, Germany, France, Spain, Italy, and Japan, and likely countless more worldwide. Oculis claims that, "Of the approximately 20 million patients who are diagnosed with DED in the U.S., about half or 10 million are considered to have moderate to severe disease. However, only 13% of DED patients receive prescription treatment, primarily with anti-inflammatory medications, and despite available therapies, most patients (87%) don't feel that their chronic DED is well-managed, which highlights a high level of dissatisfaction. Furthermore, 90% of patients discontinued their treatment altogether within one year, with the vast majority discontinuing in the first six months."

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access." [OWNERSHIP_CHART-11631]

Stock Earns "Buy" Rating

On June 10, 2026, Yi Chen, Ph.D., of H.C. Wainwright & Co. gave Oculis a "Buy" rating, with a price target of US$26.00.

Chen wrote, "licaminlimab has the potential to deliver a first-in-class precision medicine treatment in DED, in our view. We believe topline results from PREDICT-1 could become available around the end of 2026." The rating and price target are derived from an estimated market value of the firm at US$1.56 billion, all-in.

Phase 3 Trials Imminent

The company's website lists two drugs in registrational trials for ophthalmic and neuro-ophthalmic diseases: privosegtor and licaminlimab.

Both are expected to head into Phase 3 trials in the near future.

Ownership & Share Structure¹

Oculis Holding AG has a market cap of US$680.60 million, with 62.04 million shares outstanding. The company's 52-week range is US$10.52-US$34.48.

Institutions own 38.55% of shares, while Management & Insiders own 3.51%. The remaining 57.94% of shares are held by Retail.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: OCS:NASDAQ;OCS:XICE, )

MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets

Fri, 12 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/12/2026

MindBio Therapeutics delivers first prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, positioning the company in high-growth sectors including mining, aviation, and construction, while analysts highlight significant upside potential.

The biotechnology sector continues to expand rapidly as investors seek companies developing practical applications that address real-world challenges. Within this landscape, artificial intelligence tools for safety monitoring represent a particularly promising area, with the AI detector market projected to grow from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030 according to industry analysis.

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) has emerged as an innovator by focusing on voice-based biomarkers that can identify intoxication and fatigue without invasive procedures. This approach aligns with broader healthcare trends toward continuous, passive monitoring that improves outcomes across populations.

Market Opportunity in Safety and Detection Technologies

Zero-tolerance industries face ongoing pressure to reduce incidents related to substance use and exhaustion. Current screening methods often involve drawbacks such as high costs, lengthy processes, and perceptions of targeting individual workers. MindBio's technology seeks to overcome these limitations by offering scalable, non-discriminatory screening that remains effective regardless of language, dialect, accent, or gender.

The global biotechnology market, estimated at US$1.55 trillion in 2023, is forecast to reach US$3.88 trillion by 2030 with a compound annual growth rate of 13.96 percent from 2024 onward. This expansion creates favorable conditions for companies introducing novel detection solutions that can be deployed at scale.

Prototype Delivery Marks Key Milestone

On June 9, 2026, the company announced the completion of manufacturing and delivery for its first prototype Edge AI Intoxication Detection Kiosks intended for office and industrial environments. These units analyze voice patterns using more than 50 million data points from clinical trials and proprietary algorithms across over 100 acoustic parameters.

The company hopes to help create a world where voice-based biomarkers become standard in healthcare, enabling early problem detection through passive monitoring. The recent prototype milestone demonstrates tangible progress toward commercial solutions that detect intoxication and fatigue directly from voice samples.

Addressing Risks Across High-Stakes Industries

Industries such as mining, aviation, construction, and law enforcement maintain strict safety protocols, yet still encounter elevated risks from impairment. Statistics indicate that 60 percent of incidents stem directly or indirectly from alcohol, drug intoxication, or fatigue. In mining specifically, alcohol consumption rates among workers exceed 75 percent in certain regions, with over 40 percent classified as problem drinkers.

MindBio recently stated that effective screening at scale can prevent harm by identifying physiological decline early. The technology's language-agnostic nature supports broad deployment without introducing bias, while its non-invasive design reduces operational friction compared with traditional testing approaches.

Factors contributing to substance abuse risks include job stress, physical demands, injury recovery needs, and substance availability, particularly in sectors like mining. A single preventable incident in these environments can generate hundreds of millions of dollars in costs related to lost production, insurance, and medical expenses.

Strategic Partnerships and Expansion Plans

The company has already established partnerships with mines in South America and maintains active discussions with additional sectors. Current development focuses on enterprise and telehealth applications, with longer-term objectives centered on disease prediction and health optimization using the same core voice biomarker platform.

American Addiction Centers' research underscores why these industries represent logical early targets, noting that certain occupations create environments particularly conducive to substance challenges.

Analyst Perspectives and Valuation Considerations

Market observers have noted the first-of-its-kind nature of the voice detection technology. On January 26, 2026, coverage highlighted the commercialization path built on extensive clinical data. In February 2026, reporting emphasized potential efficacy in accident prevention within mining operations.

Grandview Research reported on the broader biotech opportunity, while Market and Market Analysis considered the rapid expansion of the AI detector segment. [OWNERSHIP_CHART-11539]

Most recently, technical analysis provided price targets reflecting the company's speculative profile.

¹Stewart Thomson gave Streetwise Reports a contributed technical analyst opinion rating the stock a Strong Speculative Buy, with targets of CA$1.70 short-term, CA$3.00 medium-term, and CA$6.00 long-term.

Share Structure and Ownership Profile

MindBio Therapeutics Corp. maintains a market capitalization of CA$7.9 million with 7.28 million shares outstanding. The 52-week trading range spans CA$0.50 to CA$8.00.

²Management and insiders hold approximately 5.80 percent of shares, while retail investors account for the remaining 94.20 percent.

These ownership dynamics suggest significant alignment potential with retail participation as the company advances its kiosk deployments and explores further commercial applications.

The Canadian Mining Journal reported on the technology's promise for safer operations, while Knowlton Thomas, for Techcouver, covered the underlying data foundation supporting the AI models.

The delivery of working prototypes represents a concrete advancement toward solutions that detect intoxication and fatigue from voice, supporting the company's vision for improved safety outcomes across multiple sectors.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt, )

MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets

Sat, 13 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/13/2026

MindBio Therapeutics advances prototype Edge AI kiosks for non-invasive intoxication and fatigue detection, targeting high-growth opportunities in mining, aviation, and construction sectors amid expanding biotech and AI markets.

The biotechnology sector continues to expand rapidly as investors seek companies developing practical applications in healthcare and safety technology. Market data shows the global biotechnology market reached an estimated US$1.55 trillion in 2023 and is projected to hit US$3.88 trillion by 2030, reflecting a compound annual growth rate of 13.96 percent through the end of the decade.

Within this landscape, artificial intelligence tools for detection and monitoring represent another fast-moving area, with the AI detector market expected to rise from roughly US$0.58 billion in 2025 to US$2.06 billion by 2030.

Why MindBio Therapeutics Stands Out in Voice Biomarker Development

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) has focused on voice-based biomarkers that can identify physiological changes linked to intoxication or fatigue.

The approach relies on more than 50 million data points gathered from clinical trials, combined with proprietary algorithms that analyze over 100 acoustic parameters. This foundation allows the system to operate without language, accent, or gender bias, delivering consistent results across diverse populations.

Retail investors evaluating early-stage technology companies often look for solutions that address clear pain points in large industries. MindBio's technology targets zero-tolerance environments where current screening methods can feel invasive or time-consuming. By shifting to passive voice analysis, the company aims to reduce stigma while still providing actionable safety data.

Unique Business Model Focused on Scalable, Non-Invasive Screening

The core advantage lies in the kiosk format designed for office and industrial settings. On June 9, 2026, the company announced the completion of its first prototype Edge AI Intoxication Detection Kiosks. These units analyze speech patterns to flag signs of intoxication or fatigue, offering a scalable alternative that does not single out individual workers. Chief Executive Officer Justin Hanka noted that 60 percent of workplace incidents stem directly or indirectly from alcohol, drug use, or fatigue, underscoring the need for better tools.

The company hopes to support a future in which voice-based biomarkers become routine in healthcare, enabling continuous and passive monitoring that identifies issues early. The same technology platform could eventually extend into disease prediction and health optimization, broadening the addressable market beyond initial industrial applications.

Key Catalysts Include Prototype Delivery and Sector Partnerships

Delivery of the first working prototypes marks a concrete step toward commercialization. The kiosks are intended for immediate testing in demanding environments where safety incidents carry high costs. A single preventable accident in mining, for example, can result in hundreds of millions of dollars in lost production, insurance claims, and related expenses. Studies in Chile have shown alcohol consumption rates exceeding 75 percent among mining workers, with more than 40 percent classified as problem drinkers, highlighting the urgency in that sector.

MindBio has already established partnerships with mines in South America and continues discussions with operators in aviation, construction, and law enforcement. These early relationships provide real-world validation opportunities while the company refines enterprise and telehealth versions of the platform.

Industry Timing Aligns With Rising Safety and Regulatory Pressures

MindBio recently stated that large-scale screening can help prevent harm by detecting physiological decline before incidents occur. Supporting data indicate a 10- to 20-fold increase in suicide risk during heavy intoxication, with alcohol involved in 40 to 50 percent of suicides globally.

The overall economic burden of alcohol-related harm is estimated at US$1.6 trillion annually. Industries such as mining face additional risk factors, including job stress, physical demands, and higher injury rates, according to the American Addiction Centers. These conditions make the sector particularly suitable for new detection technologies. [OWNERSHIP_CHART-11539]

Grandview Research has noted that biotechnology growth remains robust. At the same time, Market and Market Analysis considered the AI detector segment to be in rapid expansion, creating a favorable backdrop for companies commercializing voice-analysis solutions.

Analyst Perspectives and Valuation Context

The Canadian Mining Journal reported on the potential for MindBio's kiosks to reduce accidents in high-risk operations. Knowlton Thomas, for Techcouver, highlighted the scale of the underlying dataset and the transition from research to commercialization.

1Most recently, Stewart Thomson gave Streetwise Reports a contributed technical analyst opinion that assigned a Strong Speculative Buy rating, with short-term, medium-term, and long-term price targets of CA$1.70, CA$3.00, and CA$6.00, respectively.

Share Structure and Ownership Overview

MindBio Therapeutics Corp. reports a market capitalization of CA$7.9 million and 7.28 million shares outstanding. The 52-week trading range has spanned CA$0.50 to CA$8.00.

²Management and insiders hold approximately 5.80 percent of the shares, while retail investors account for the remaining 94.20 percent.

Upcoming milestones such as further prototype deployments and additional industry partnerships could provide catalysts for investor attention. The combination of a defined market need, advancing technology, and favorable sector trends positions the company for continued development in the voice-biomarker space.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt, )

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors

Fri, 12 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/12/2026

Explore how MindBio Therapeutics is advancing voice-based AI detection for intoxication across mining, aviation, and other industries, backed by strong market trends and analyst targets.

The biotechnology sector continues to expand rapidly as investors seek companies that combine innovative technology with practical applications in safety and health. MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) is developing voice-based AI solutions designed to identify signs of intoxication and fatigue, offering potential value in environments where human performance directly affects safety outcomes.

Market Opportunity in AI-Driven Detection

Global demand for advanced detection tools is rising due to the high costs associated with workplace incidents and substance-related issues. The biotechnology market, estimated at US$1.55 trillion in 2023, is projected to reach US$3.88 trillion by 2030 according to Grandview Research, reflecting a compound annual growth rate of 13.96%. Within this landscape, the AI detector market is also expanding quickly, with projections from MarketsandMarkets showing growth from approximately US$0.58 billion in 2025 to US$2.06 billion by 2030. These trends highlight increasing interest in scalable technologies that support continuous monitoring without invasive procedures.

Voice analysis represents one emerging approach within this space. By examining acoustic parameters, such tools can potentially flag impairment from substances including alcohol, cannabis, cocaine, narcotics, and psychedelics, as well as general fatigue. This capability aligns with needs in high-stakes industries where early identification can help reduce risks.

Why MindBio Stands Out with Its Core Technology

MindBio Therapeutics Corp. recently announced the launch of its lead commercial software called Intox AI. This platform adds analytical features to existing capabilities, enabling the detection of multiple forms of impairment directly from voice samples. The company aims to support applications in industrial, aviation, law enforcement, mining, and civilian settings.

The company hopes to contribute to a world where voice-based biomarkers become standard in healthcare, supporting continuous and passive monitoring that identifies issues early.

Justin Hanka, the CEO, noted that the launch marks a meaningful step forward for testing across substances that influence performance and safety, with prototype kiosks scheduled for delivery soon.

Unique Business Model and Competitive Edge

MindBio's approach leverages more than 50 million data points from clinical trials, along with proprietary algorithms analyzing over 100 acoustic parameters. This foundation allows the technology to move from research into commercial use. The model focuses initially on enterprise deployments such as kiosks placed in operational environments, with plans to extend later into telehealth and predictive health applications.

Unlike traditional testing methods that may require physical samples or scheduled screenings, voice-based detection offers the possibility of non-intrusive, rapid assessment. This distinction could prove useful in sectors that operate under strict safety protocols and need efficient ways to maintain compliance.

Key Catalysts and Deployment Timeline

The company is preparing to roll out Edge AI voice detection kiosks targeting mining and aviation sectors beginning in June 2026. These deployments are intended for large-scale testing in zero-tolerance environments. Partnerships are already underway with mines in South America, and discussions continue with additional industries, including construction and law enforcement.

Future development pathways include disease prediction and health optimization features once enterprise and telehealth functions are established. These steps position the company to address both immediate safety needs and longer-term health monitoring opportunities.

Industry Timing and Supporting Trends

MindBio recently stated that widespread screening can help limit harm by identifying physiological changes associated with intoxication. Statistics cited include a 10-20x increase in suicide risk during heavy intoxication and estimates that 40-50% of suicides involve alcohol, with global alcohol-related harm costs reaching around US$1.6 trillion. Factors such as job stress, physical demands, and injury risks contribute to higher substance use in certain occupations, as noted by the American Addiction Centers, which highlights the mining sector in particular. [OWNERSHIP_CHART-11539]

Reports from the field reinforce these points. The Canadian Mining Journal reported that studies in Chile show alcohol consumption among mining workers exceeding 75%, with over 40% classified as problem drinkers. A single incident in such settings can lead to substantial financial impacts from lost production and related expenses.

Analyst Perspectives and Valuation Context

Industry observers have commented on the technology's potential. Knowlton Thomas, for Techcouver, highlighted the commercialization path based on extensive clinical data.

¹More recently, Stewart Thomson gave Streetwise Reports a contributed technical analyst opinion that rated MindBio as a Strong Speculative Buy, with short-term, medium-term, and long-term price targets of CA$1.70, CA$3.00, and CA$6.00, respectively.

These views reflect interest in how the company's software and kiosk strategy could align with growing safety requirements across multiple sectors.

Share Structure and Ownership Details

MindBio Therapeutics Corp. maintains a market capitalization of CA$7.9 million based on 7.28 million shares outstanding. The 52-week trading range has spanned CA$0.50 to CA$8.00.

²Management and insiders hold approximately 5.80% of shares, while retail investors account for the remaining 94.20%.

According to the company's latest presentation, According to the company's latest presentation the focus remains on scaling voice detection capabilities in key industries while exploring additional health-related uses over time. This measured approach supports ongoing development within a growing market for AI-enabled safety tools.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt, )

Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market

Wed, 10 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/10/2026

Grey Matters Health advances its Alzheimer's neuroimaging strategy with fresh financing and plans for the first U.S. brain-specific PET clinic, capitalizing on rising demand for early detection tools.

The Alzheimer's disease diagnostics sector is experiencing strong expansion as demand rises for earlier and more precise identification of cognitive conditions. Market data indicate the space reached US$9.40 billion in 2025 and is projected to climb to US$26.21 billion by 2035, supported by the need for minimally invasive biomarker testing and imaging solutions.

According to a May report from Precendence Research on the Alzheimer's disease diagnostics market, the sector was valued at US$9.40 billion in 2025 and was projected to reach US$26.21 billion by 2035. Brain imaging already accounts for a sizable portion of activity, reflecting the growing reliance on tools that can reveal structural and amyloid changes associated with the disease.

Within this environment, Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) has taken concrete steps to build dedicated capacity. The company recently completed the first tranche of a non-brokered private placement, securing CA$500,000 through the issuance of 1,250,000 units priced at CA$0.40 each. Insider participation reached CA$184,000, conducted under applicable related-party guidelines that exempted the transaction from certain valuation and approval steps because values remained below the 25 percent market-capitalization threshold. [OWNERSHIP_CHART-9895]

The closing of the first tranche of its previously announced non-brokered private placement financing. Cash finder's fees of CA$8,000 and 20,000 finder's warrants were also issued in connection with the tranche. The proceeds are earmarked for advancing the Alzheimer's program, including preparations for the company's initial U.S. brain-focused neuroimaging clinic, along with general corporate and working-capital needs.

Grey Matters has outlined a distinctive model centered on specialized positron emission tomography, or PET, imaging. PET is a nuclear-medicine technique that uses a small amount of radioactive tracer to visualize metabolic processes in tissue; when optimized for the brain, it can highlight early biological markers linked to Alzheimer's. The company intends to deploy this technology through a network of dedicated outpatient clinics rather than relying on general hospital radiology departments.

¹In a March 26 report, Stewart Thomson examined Grey Matters Health Inc.'s entry into the Alzheimer's disease diagnostics sector and described the company as "a Canadian healthcare company." The analyst highlighted the focus on early-stage detection using advanced, FDA-cleared brain-specific PET scanners and assigned technical price targets that have since been attained.

Artificial intelligence is simultaneously reshaping imaging workflows. The U.S. Food and Drug Administration had authorized 1,451 AI-enabled medical devices by the end of 2025, with radiology representing 76 percent of those clearances. Such tools assist in prioritizing scans, automating measurements, and supporting earlier identification of disease progression when applied to MRI and PET datasets.

The Imaging Wire reported in March that the U.S. Food and Drug Administration had authorized 1,451 AI-enabled medical devices through the end of 2025. Additional commentary noted that imaging volumes continue to rise due to aging populations and expanded screening, positioning AI as a meaningful aid for workflow efficiency and diagnostic support.

Additional commentary published by Becker's Hospital Review on May 18 described radiology as being at "a pivotal inflection point" as imaging volumes continued to increase across hospitals. Grey Matters plans to open its first NovaScan Neuroimaging Clinic in Davie, Florida, inside the HCA Florida University Medical Office Building. Roughly six million residents live within a one-hour drive, providing a sizable local population for services focused on Alzheimer's detection and related neurological conditions such as epilepsy and Parkinson's disease.

According to the company's May 2026 presentation, the first NovaScan Neuroimaging Clinic is planned for Davie, Florida, at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus. The facility will employ the CareMiBrain PET system, an FDA-cleared brain-only scanner introduced in 2024 that operates without an accompanying CT component. Each clinic is expected to require approximately 1,750 square feet and roughly US$1.1 million in capital outlay for equipment and build-out. Catalyst MedTech is assisting with clinical and regulatory matters, American Molecular Imaging will provide radiology interpretation, and GE HealthCare Technologies will supply the Vizamyl F18-PET tracer for the Florida site.

The financing remains available for additional closings expected on or before June 30, 2026, giving the company flexibility to accelerate clinic development.

Grey Matters said the offering remains open.

²Management and insiders hold approximately 11 percent of shares, while institutions own about 21 percent, with the balance held by retail investors. Leading holders include Alpha North Asset Management at 20.52 percent, Chief Executive Officer Christopher Moreau at 5.05 percent, Chairman Harry Bloomfield at 1.97 percent, Chief Financial Officer James Kinley at 1.4 percent, and Director Rajpaul Attariwala at 1.2 percent.

Grey Matters currently has 54.1 million shares outstanding, a market capitalization of US$1.37 million, and a 52-week trading range of US$0.035 to US$0.10.

By combining targeted financing with a focused clinic rollout and alignment with broader trends in early-detection imaging, Grey Matters Health is establishing a platform positioned to address rising clinical demand in the Alzheimer's diagnostics field.

Important Disclosures:

Grey Matters Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGW0:FRA; AGNPF:OTCQB, )

Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries

Thu, 11 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/11/2026

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) delivers first Edge AI intoxication detection kiosk prototypes for mining, aviation, and construction safety screening.

On June 9, 2026, MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) announced the completed manufacture and delivery of its first prototype Edge AI Intoxication Detection Kiosks. These prototypes are designed for office and industrial use to detect intoxication and fatigue in workplace settings, with the goal of increasing safety in a non-invasive way.

Current screening techniques in zero-tolerance industries can be invasive, time-consuming, costly, and make a worker appear targeted. MindBio aims to provide the benefits of screening without the pitfalls. "The core reason why a company wants to do this is that 60% of incidents are caused by alcohol and drug intoxication, directly or indirectly, and 60% by intoxication and fatigue," MindBio CEO, Justin Hanka, said in an interview with Streetwise Reports.

When questioned about how the technology might interpret different languages, dialects, or speech patterns, Hanka said, "It's language agnostic. It's accent agnostic," noting that the markers tested change uniformly with intoxication, regardless of gender, dialect, or language. The application of this AI system allows for the potential to administer tox screenings in a non-discriminatory and scalable way.

The company hopes to help create ". . . a world where voice-based biomarkers are a standard component of healthcare — enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere" and describes its vision as developing ". . . a world where voice-based biomarkers are a standard component of healthcare—enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

Hanka said in the June 9 release, "The delivery of MindBio's first prototype model Edge AI intoxication and fatigue detection kiosks is a positive advancement for the Company in delivering useful solutions to detect intoxication and fatigue from voice."

Better Detection Needed in Zero-Tolerance Industries

MindBio recently stated that screening for drug and alcohol intoxication at scale can prevent unnecessary harm through the detection of physiological decline. The company offered statistics that estimate a 10-20x increase in suicide risk while heavily intoxicated. It also claims that 40-50% of suicides involve alcohol, noting that the global alcohol harm cost sits at around US$1.6 trillion.

The risk of addiction and drug or alcohol abuse rises due to many factors, like parental monitoring, peer pressure, socioeconomic status, type of substance, stress, drug availability, and occupation, according to the American Addiction Centers. They cite the mining industry as "particularly conducive to substance abuse," due to job stress, physical demand, and injuries from prolonged work.

The entire biotech sector has shown exponential growth recently. "The global biotechnology market size was estimated at US$1.55 trillion in 2023 and is projected to reach US$3.88 trillion by 2030, growing at a CAGR of 13.96% from 2024 to 2030," said Grandview Research. In September 2025, Market and Market Analysis considered the AI detector market as "undergoing rapid expansion, with estimates projecting a substantial market value surge from approximately US$0.58 billion in 2025 to US$2.06 billion in 2030."

Experts Anticipate First-of-Its-Kind Tech

On February 3, 2026, The Canadian Mining Journal reported that, "Studies in Chile reveal that alcohol consumption among mining workers exceeds 75%, with over 40% classified as problem drinkers." The article noted the potential efficacy of MindBio's kiosks in accident prevention, saying, "A single preventable incident can cost a mining company hundreds of millions in lost production, union boycotts, and insurance and medical expenses." [OWNERSHIP_CHART-11539]

Knowlton Thomas, for Techcouver, wrote on January 26, 2026, that ". . . Leveraging more than 50 million data points from drug and alcohol clinical trials and proprietary algorithms across over 100 acoustic parameters, MindBio is now commercializing its technology."

¹Most recently, Stewart Thomson gave Streetwise Reports a contributed technical analyst opinion about MindBio on April 1, 2026. Thomson rated MindBio as a 'Strong Speculative Buy', with a short-term price target of CA$1.70, a medium-term price target of CA$3.00, and a long-term price target of CA$6.00.

Multiple Industries Targeted

Currently, MindBio is creating inroads into the mining, aviation, construction, and law enforcement industries. The company is already partnering with mines in South America and is in talks with other industries.

While enterprise and telehealth capacities are in development right now, future plans include disease prediction and health optimization.

Ownership & Share Information²

MindBio Therapeutics Corp. has a market cap of CA$7.9 million, with 7.28 million shares outstanding. The company's 52-week trading range is CA$0.50-CA$8.00.

Management and Insiders own approximately 5.80% of MindBio Therapeutics shares, with Retail investors holding the remaining 94.20%.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt, )

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market

Wed, 10 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/10/2026

Explore how ORIC Pharmaceuticals is advancing its oncology pipeline with key catalysts ahead, amid rising global demand for innovative cancer treatments and strong analyst support.

The oncology sector continues to attract significant attention from investors as global demand for advanced cancer therapies accelerates. With cancer cases projected to climb and treatment costs rising steadily, companies developing novel approaches to overcome therapeutic resistance stand out as compelling opportunities in the current market environment.

ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) has built a focused clinical-stage platform centered on addressing treatment resistance in cancer patients, positioning the company to potentially capture meaningful value as innovation reshapes care standards.

Its strategy emphasizes targeted mechanisms that differentiate its candidates from existing options, particularly in areas with high unmet need such as prostate cancer and non-small cell lung cancer. This approach aligns well with broader industry trends favoring precision therapies that improve outcomes while managing complexity.

The company recently granted stock options and restricted stock units to new employees under its 2022 Inducement Equity Incentive Plan, a standard practice that supports talent acquisition without immediate dilution concerns for existing shareholders. A June 5, 2026, Stockwatch article detailed the grants, which were approved by the Compensation Committee and carry typical vesting schedules tied to continued service.

ORIC's pipeline centers on two primary assets advancing toward later-stage development. Rinzimetostat targets the EED subunit of the polycomb repressive complex 2 and is being evaluated for metastatic castration-resistant prostate cancer. Enozertinib, a brain-penetrant EGFR inhibitor, addresses exon 20 insertion and atypical mutations in non-small cell lung cancer. The company's pipeline reflects a deliberate focus on resistance mechanisms that limit current standards of care.

Market Tailwinds Support Innovation

Global medicine usage is expected to exceed four trillion doses daily by 2030, driven largely by innovative oncology and immunology therapies in developed markets, according to IQVIA, which discussed the global pharma market projection for 2026. Although biopharma funding moderated between 2024 and 2025, levels remained above pre-pandemic norms and ranked among the stronger years of the past decade, per a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.

Cancer incidence continues to rise, with the American Cancer Society anticipating 2.1 million new cases and more than 626,000 deaths in 2026, as noted in a March 26, 2026, article by Kinjel Shah for Yahoo Finance. Advances in genomic sequencing and artificial intelligence are accelerating biomarker identification and earlier intervention, yet treatment costs in the United States are projected to reach over US$245 billion by 2030, according to an article written by Keith Speights for The Motley Fool discussing rising care costs.

These dynamics underscore the need for companies to balance scientific progress with operational efficiency, a point emphasized by BCG, which talked about trends biopharma companies need to be aware of in 2026. ORIC's emphasis on resistance pathways and combination strategies appears well-timed for this environment.

Analyst Sentiment and Upcoming Milestones

Recent analyst commentary highlights ORIC's progress.

David Nierengarten of Wedbush issued an Outperform rating following positive Phase 3 data on sunvozertinib in EGFR exon 20 insertion-positive non-small cell lung cancer. [OWNERSHIP_CHART-11626]

Robert Burns of H.C. Wainwright & Co. maintained a Buy rating with a US$25 price target, citing a catalyst-rich period that includes program updates for ORIC-944 and data readouts for enozertinib monotherapy and combination approaches in the second half of 2026.

In its investor presentation, the company outlines plans to initiate a global Phase 3 trial for rinzimetostat in post-abiraterone metastatic castration-resistant prostate cancer during the first half of 2026, with a program update expected later in the year. For enozertinib, key readouts on monotherapy and combination data in first-line EGFR exon 20 insertion-positive disease, plus atypical mutation data, are anticipated in the second half of 2026.

ORIC Pharmaceuticals Inc. maintains a market capitalization of US$776.38 million and 103.52 million shares outstanding. Its 52-week trading range spans US$7.23 to US$14.93.

¹Institutions hold 68.30 percent of shares, while strategic investors account for the remaining 31.70 percent.

These elements collectively frame an investment case centered on disciplined pipeline advancement within a growing therapeutic area, offering retail investors a clear lens on potential milestones through the balance of the year.

Important Disclosures:

Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: ORIC:NASDAQ, )

Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close

Tue, 09 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/09/2026

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) closed the first CA$500,000 tranche of a financing that the company said will support its Alzheimer's disease program and planned U.S. brain-specific neuroimaging clinic.

Grey Matters Health Inc. (GREY:CSE; AGW0:FRA; AGNPF:OTCQB) announced the closing of the first tranche of its previously announced non-brokered private placement financing.

According to the company, gross proceeds from the first tranche totaled CA$500,000 from the sale of 1,250,000 units at an issue price of CA$0.40 per unit. The financing was originally announced on April 22, 2026, and updated on May 25, 2026.

The company reported that certain insiders participated in the first tranche in the amount of CA$184,000. Grey Matters stated that the participation constituted a related party transaction under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions. The company said it relied on exemptions from the valuation and minority shareholder approval requirements contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 because neither the fair market value of the units purchased by insiders nor the consideration paid by insiders exceeded 25% of the company's market capitalization.

Grey Matters also reported that it paid cash finder's fees of CA$8,000 and issued 20,000 finder's warrants in connection with the first tranche.

The company stated that proceeds from the offering will be used to advance its Alzheimer's Disease program toward the opening of its first U.S. brain-specific neuroimaging clinic, as well as for general and administrative expenses and working capital purposes.

Grey Matters said the offering remains open and that it expects to close additional tranches on or before June 30, 2026.

Early Detection and AI Reshape Alzheimer's Imaging

According to a May report from Precendence Research on the Alzheimer's disease diagnostics market, the sector was valued at US$9.40 billion in 2025 and was projected to reach US$26.21 billion by 2035. The report stated that growth had been driven by "the growing demand for early Alzheimer's detection and minimally invasive, biomarker-based diagnostics." The report also noted that brain imaging represented 38% of the market in 2025, while imaging technologies accounted for 45% of the total market share. According to the report, "imaging methods are becoming increasingly employed to identify early structural and amyloid markers in the brain to help diagnose patients," while "rapid advancements in investments in imaging infrastructure and the increasing inclination for high-resolution gadgets for evaluating neurological diseases" also contributed to market growth.

The report further stated that artificial intelligence continued to play a growing role in Alzheimer's diagnostics. According to the report, "AI and machine learning are being integrated and are becoming increasingly adopted to improve accuracy, automate analysis, and facilitate earlier detection of the progression of Alzheimer's disease." It also noted that AI-powered tools were helping clinicians analyze MRI, PET, and biomarker data and "detect the onset of Alzheimer's disease." The report added that "the elderly population has been increasing worldwide, and there is a greater focus on screening and care provision for cognitive impairments at the first stage of cognitive decline."

The broader imaging sector also continued to expand its use of AI technologies. The Imaging Wire reported in March that the U.S. Food and Drug Administration had authorized 1,451 AI-enabled medical devices through the end of 2025. According to the publication, radiology accounted for 1,104 devices, or 76% of all AI-enabled medical device authorizations. The report stated that the updated figures showed "continued momentum for medical imaging" and that radiology maintained its position as the medical specialty with the largest number of AI-related clearances.

Additional commentary published by Becker's Hospital Review on May 18 described radiology as being at "a pivotal inflection point" as imaging volumes continued to increase across hospitals, emergency departments, and outpatient centers. The publication wrote that demand for imaging services had expanded because of "aging populations, increased utilization of advanced imaging, broader screening programs, and the ongoing shift toward data-driven diagnostics." Becker's also noted that artificial intelligence had demonstrated "meaningful potential" in areas including workflow prioritization, quality assurance, detection support, and operational efficiency, while healthcare organizations continued evaluating how AI technologies could be integrated into imaging operations.

Analyst Discussed Alzheimer's Diagnostic Clinic Strategy

¹In a March 26 report, Stewart Thomson examined Grey Matters Health Inc.'s entry into the Alzheimer's disease diagnostics sector and described the company as "a Canadian healthcare company." Thomson wrote that the company's business model centered on brain-optimized Positron Emission Tomography imaging, stating that "this plan will make the company's main business diagnosing Alzheimer's disease, using high-technology brain-optimized Positron Emission Tomography (PET) scans for diagnosis."

The report also referenced "the goal of capturing a US$6.9 billion emerging market" and highlighted the company's plans to focus on Alzheimer 's-related neuroimaging services.

According to Thomson, Grey Matters was "entering the Alzheimer's Disease (AD) diagnostic market segment with plans to establish a network of dedicated neuroimaging medical clinics in the U.S." He added that the proposed facilities were expected to utilize "the most advanced, FDA-cleared brain-specific PET scanner to focus on early-stage detection of the disease."

Thomson assigned the company a "Technical Rating: Strong Speculative Buy" and identified short-, medium-, and long-term price targets of CA$0.08, CA$0.17, and CA$0.40, respectively. All three targets have been achieved. [OWNERSHIP_CHART-9895]

Neuroimaging Clinic Development Plans

According to the company's May 2026 presentation, the first NovaScan Neuroimaging Clinic is planned for Davie, Florida, at the HCA Florida University Medical Office Building on the HCA Florida University Hospital campus. The presentation states that approximately six million people live within a one-hour drive of the location.

The company said the clinic will utilize the CareMiBrain PET Brain Scanning System, which it described as an FDA-cleared brain-specific PET imaging system. The presentation states that the system received FDA clearance in 2024 and that it operates without a CT scan component.

Grey Matters' presentation states that NovaScan Neuroimaging Clinics are intended to focus on brain-specific neuroimaging, including Alzheimer's disease detection. The company also identified epilepsy, Parkinson's disease, multiple sclerosis, brain cancers, and other indications using new tracers as areas of focus for the clinic model.

The presentation further states that Grey Matters plans to establish a national network of private U.S. neuroimaging medical clinics and identifies NovaScan Neuroimaging Clinics as the branding for its Alzheimer's initiative. The company reported that Catalyst MedTech is providing clinical solutions and regulatory support for the initiative, while American Molecular Imaging will provide radiology reading services for the company's U.S. neuroimaging clinics. Grey Matters also stated that GE HealthCare Technologies will supply Vizamyl F18-PET tracers for its Florida clinics.

According to the presentation, a NovaScan Neuroimaging Clinic is expected to occupy approximately 1,750 square feet and require capital expenditures of approximately US$1.1 million, including scanner acquisition and clinic buildout costs. The company reported that the CareMiBrain system will be the first such system purchased for operation in the United States.

Ownership and Share Structure²

Management and insiders own about 11% of the company, and about 21% is owned by institutions. The rest is with retail.

Top shareholders include Alpha North Asset Management with 20.52%, Chief Executive Officer Christopher Moreau with 5.05%, Chairman of the Board Harry Bloomfield with 1.97%, Chief Financial Officer James Kinley with 1.4%, and Director Rajpaul Attariwala with 1.2%.

Grey Matters has 54.1 million outstanding shares, a market cap of US$1.37 million, and a 52-week range of US$0.035 - US$0.10.

[SMNLINSERT]

Important Disclosures:

Grey Matters Health has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 26, 2026

For the quoted article (published on March 26, 2026), Grey Matters Health has paid Street Smart, an affiliate of Streetwise Reports, US$3,000.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: GREY:CSE; AGW0:FRA; AGNPF:OTCQB, )

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth

Mon, 08 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/08/2026

ORIC Pharmaceuticals Inc. (ORIC:NASDAQ) granted 34,800 stock options and 5,900 restricted stock units to new employees as analysts issue "Buy" ratings for the year ahead.

ORIC Pharmaceuticals Inc. (ORIC:NASDAQ), a clinical stage oncology company focused on developing therapeutic resistance treatments, announced new stock options, according to a June 5, 2026, Stockwatch article. The company granted 34,800 non-qualified stock options and 5,900 restricted stock units to two new non-executive employees who began working for ORIC in May 2026.

The company said in the release: "These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient’s continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC’s common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36^th) of the remaining shares vesting each one-month period thereafter. One-third (1/3^rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan."

These inducement grants were approved by ORIC's Compensation Committee of the Board of Directors.

ORIC Pharmaceuticals Inc. is an American biopharma company focused on oncology treatments and improving patients' quality of life via overcoming treatment resistance. The company's pipeline includes:

Rinzimetostat: an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer
Enozertinib: a brain penetrant inhibitor targeting EGFR exon 20 and EGFR atypical mutations, being developed for NSCLC

Cancer Research Needs Grow

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

Analysts Look Forward to Next Results

On June 3, 2026, David Nierengarten of Wedbush gave ORIC an "Outperform" rating after seeing the positive primary results from the Phase 3 "WU -KONG28 study of sunvozertinib monotherapy vs. platinum -based chemotherapy in 1L advanced NSCLC with EGFR exon20ins."

Later, on June 8, 2026, Robert Burns of H.C. Wainwright & Co. reiterated its "Buy" rating for the company and its price target of US$25. Burns noted a "catalyst-rich" year ahead for ORIC, such as: "(1) a program update for ORIC-944 in 2H26; (2) presentation of updated data for enozertinib monotherapy in 1L EGFR exon 20 insertion-positive NSCLC and initial results for the combination with subcutaneous amivantamab in 2H26." These catalysts are precisely why Burns will be watching the company over the next few months. [OWNERSHIP_CHART-11626]

Two Drugs in the Pipeline

In its investor presentation, ORIC claims its drugs are in a late-stage clinical pipeline, noting that ". . . rinzimetostat (ORIC-944) and enozertinib (ORIC-114) [are] rapidly advancing towards potential Phase 3 initiations."

Near-term catalysts for Rinzimetostat for MCRPC are to initiate the first global Phase 3 trial in post-abiraterone mCRPC in the first half of 2026 and to provide a program update in the second half of the year.

Near-term catalysts for enozertinib for NSCLC include "1L EGFR exon 20 monotherapy data and combination data with SC amivantamab" and "1L EGFR atypical monotherapy data", in the second half of 2026.

Ownership & Share Information¹

ORIC Pharmaceuticals Inc. has a market cap of US$776.38 million, with 103.52 million shares outstanding. The company's 52-week range is US$7.23-US$14.93.

Institutions own 68.30% of shares, while Strategic Investors own 31.70%.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: ORIC:NASDAQ, )

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity

Wed, 10 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/10/2026

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) launches Intox AI, detecting intoxication via voice, targeting mining and aviation in a US$2.06B market.

MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) announced the launch of its lead commercial software — Intox AI — on June 5, 2026. MindBio is focused on creating biotech to help detect intoxication and prevent accidents in industrial, aviation, law enforcement, mining, and civilian situations. The company hopes to help create ". . . a world where voice-based biomarkers are a standard component of healthcare — enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere" and describes its vision as developing ". . . a world where voice-based biomarkers are a standard component of healthcare—enabling continuous, passive health monitoring that catches problems early and improves outcomes for everyone, everywhere."

Intox AI allows adding news analytical capabilities to the company's software, enabling the detection of cocaine, cannabis, alcohol, psychedelic, and narcotic abuse, as well as regular fatigue, from the human voice.

Justin Hanka, MindBio CEO, said in the release: "The launch of Intox AI is a significant advancement for drug and alcohol testing across a range of substances that affect human performance and safety. The company is on track to deliver its first prototype testing kiosks shortly and is delighted that the core software is ready for testing and validation."

Intoxication Detection Methods Needed

Experts See MindBio as Problem-Solver

Tackling New Issues

Currently, MindBio is creating inroads into the mining, aviation, construction, and law enforcement industries.

According to the company's latest presentation, MindBio intends to deploy its Edge AI voice drug and alcohol detection kiosks for the mining and aviation sectors in June 2026, hoping to test at a large scale in zero-tolerance industries. The company is already partnering with mines in South America and is in talks with other industries.

While enterprise and telehealth capacities are in development right now, future plans include disease prediction and health optimization.

Ownership & Share Information²

MindBio Therapeutics Corp. has a market cap of CA$7.9 million, with 7.28 million shares outstanding. The company's 52-week trading range is CA$0.50-CA$8.00.

Management and Insiders own approximately 5.80% of MindBio Therapeutics shares, with Retail investors holding the remaining 94.20%.

Important Disclosures:

MindBio Therapeutics Corp. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of MindBio Therapeutics Corp.
Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

1. Disclosure for the quote from the Stewart Thomson article published on April 1, 2026

For the quoted article (published on April 1, 2026), MindBio Therapeutics Corp. has paid Street Smart, an affiliate of Streetwise Reports, US$3,500.
Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

For additional disclosures, please click here.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt, )

From Healthcare IT Vendor to AI-Driven Holding Company

Fri, 05 Jun 2026 00:00:00 PST

Source: Mike Sheikh 06/05/2026

Healthcare Triangle Inc.'s (HCTI:NASDAQ) Spanish AI acquisition delivers US$34M in revenue and a near-US$40M agentic AI run rate, while shares still trade at just 1x cash.

Healthcare Triangle Inc. (HCTI:NASDAQ) looks like one of the more unusual microcap transformation stories in the market today. On the surface, investors may still associate the company with its earlier phase as a healthcare IT services vendor, which includes periods of dilution, reverse splits, and operating challenges. But underneath that legacy narrative, the company has been rebuilt into a three-part holding company structure that now includes a U.S. healthcare IT services base, an Asia-Pacific generative AI healthcare software arm, and a newly acquired Spanish AI-powered customer engagement and insurance distribution platform. The company has a revenue run rate approaching US$40 million tied to agentic AI, a market capitalization just over US$4 million, trades at 1x cash, and even has a US$2.0 million share repurchase plan in place. The disconnect between what the company was and what it has morphed into is becoming difficult to ignore.

The key change is that HCTI is no longer trying to scale as a labor-intensive healthcare IT vendor. Management is now using the public vehicle to assemble profitable operating businesses with recurring or scalable revenue characteristics, then connect them through cross-selling opportunities in healthcare, insurance, and digital engagement. The January 2026 acquisition of Teyame 360 S.L. and Datono Mediacion S.L. appears to be the clearest evidence of that strategy. They brought in a business that generated US$34 million in revenue and US$4.2 million in EBITDA in 2025 and is expected to account for the majority of the company's revenue and profitability going forward. For investors willing to look beyond the company's difficult financing history, HCTI increasingly resembles an AI-backed holding company trading at a valuation that still reflects its past more than its present.

Three-Business Structure

HCTI is attempting to pivot from a traditional healthcare IT services vendor into a holding-company-styled business with three distinct business segments.

Purpose Health: Their U.S. healthcare IT Life Sciences services business (Legacy)
QuantumNexis: A global GenAI healthcare SaaS arm
Teyame/Datono: New acquisition, an AI-powered customer engagement and insurance distribution platform in Spain

Management has created a blend of service revenue, software optionality, and acquisition-backed earnings power that did not exist when investors were viewing the company solely as a traditional healthcare IT contractor.

Purpose Health

Purpose Health is HCTI's legacy healthcare IT business. IT services are quite labor-intensive, but it puts the IT manager in a position to choose software and applications. Their teams have implemented and managed major platforms like Epic, MEDITECH, and Cerner, servicing roughly 100 – 150 hospitals in the recent past. These relationships form the basis to sell new products and service in the future.

In HCTI's new structure, Purpose Health serves three strategic roles:

Fund Operations: Generate stable services revenue to cover overhead and debt service
Unlock Distribution: Serve as a trusted referral partner to sell QuantumNexis and other SaaS/AI products into these established hospital and health system relationships
Provide Credibility: Anchor HCTI's reputation as a HITRUST-certified, healthcare-native company instead of a generic AI vendor

Healthcare providers are looking to deliver personalized patient experiences. Purpose Health is the cash-generating base that keeps HCTI relevant with hospital CIOs and gives it access to its multitude of relationships in the acute and specialty care facilities to leverage its SaaS and AI products.

QuantumNexis

QuantumNexis is a wholly owned subsidiary with a focus on sales in Malaysia and the broader SE Asia region. The subsidiary has 2 primary business lines tied to long-term servicing agreements. Ziloy is a mental health app targeting an untapped market in the Asia-Pacific. It's being used by Malaysia's only on-demand lifestyle digital insurer to support mental wellness for small and medium-sized enterprises (SMEs). Their other business line is called Ezovion, which is a smart hospital information management system (HIMS) and EHR platform. They leverage this health technology platform to deliver solutions for providers and insurers, like mental wellness and behavioral health solutions at scale through their apps, or use their analytics to control hospital expenditures.

While the focus is on Asia-Pacific, a new Saudi Arabian joint venture could start contributing to revenue this year. In February 2026, the company announced a partnership with Golden Code Holdings to address the US$70 billion healthcare market in Saudi Arabia. The JV is intended to position QuantumNexis as a preferred AI and cloud partner capable of scaling digital health innovation through their suite of products that include: Ezovion, Ziloy, and Readabl.ai. These solutions are expected to support hospitals, clinics, and enterprise healthcare groups in modernizing workflows, improving care coordination, and enabling real‑time insights that provide for better patient care. These subsidiaries are expected to contribute US$2.0 million to top-line revenues in 2026, and the Saudi Arabian deal represents potential upside to that goal.

The top digital wallet and payment solution used by 90% of consumers in Malaysia is called Touch 'n Go. It also announced a partnership with QuantumNexis Malaysia, which signed a strategic partnership in February 2026 with TNG Digital to embed Ziloy, which is a clinically validated digital mental health services app, into the TNG eWallet. Through the eWallet, the app will reach 25 million Malaysians. Details of the deal are forthcoming, but it appears to be transaction-like revenue from embedded distribution and monetization engine rather than a standalone app that has to acquire users one at a time.

Teyame/Datono Acquisition

The most transformational move in the HCTI story so far is the acquisition of Teyame 360 and Datono Mediacion in Spain. These companies operate a technology-driven omnichannel customer experience that sells a number of different insurance products, providing:

Outbound Customer Engagement Platform.
Appointment scheduling and customer engagement.
Credit and insurance product distribution and brokerage services.

Unlike many microcap software deals that promise future growth but offer little near-term earnings support, this acquisition brought in an operating business running at scale. The Spanish entity recorded US$34 million in revenue and US$4.2 million in EBITDA in 2025. Management has projected roughly US$38 million in revenue and US$5 million in EBITDA over the course of the next 12 months. In addition, the company is embedding an "agentic" powered AI that makes outbound voice outreach using AI agents with intentionally imperfect, human-like voices capable of conducting natural conversations with customers, booking appointments, and driving sales. Their current focus is on the insurance business, but they plan to quickly integrate health and wellness products. The Teyame/Datono acquisition gives HCTI something it lacked for years, which is a profitable, scalable operating engine that can anchor the broader holding company strategy.

Financial Review

Healthcare Triangle's latest quarterly filing shows dramatic top-line growth, but it was unable to break into the black. In Q1 2026, revenue jumped to US$9.9 million, up 166% YoY from US$3.7 million a year ago, driven largely by the consolidation of the Teyame/Datono (Spanish AI) and QuantumNexis acquisitions. Gross profit also surged 627% YoY to US$2.4 million, while gross margin improved to 24.3% from 8.9% in the prior-year quarter, reflecting a shift toward higher-margin SaaS and AI revenue.

Despite an increase in revenues and margins, the company was still operating in the red but showing improvement. HCTI's Q1 2026 operating loss was US$3.6 million, but this represented an 18.4% improvement YoY. Another promising trend was in the fixed operating expenses as a percentage of sales. Stripping out the variable marketing expense and amortization costs, core operating expenses improved 1.5% YoY.

At the end of Q1, the balance sheet shows total assets of US$80.2 million, including US$55.2 million of intangible assets and US$2.9 million of goodwill, largely tied to acquisitions. The company ended the quarter with US$4.3 million in cash, but also has a factoring facility tied to the Spanish acquisition, helping with the cash flow. Total liabilities were US$27.5 million, and total stockholders' equity was US$52.7 million. Assuming the note is paid off, the book value per share is roughly US$19 -20/share or 7.7x the current market price. This disconnect is exactly what makes the stock interesting to investors, but it also reflects the reality that it's a show-me story as investors remain vigilant for the turn to profitability.

Capital Structure Reset

No bullish thesis on HCTI is complete without acknowledging that the stock has been in a downtrend, testing shareholder confidence. Over the past year, the company needed capital to fund operations and acquisitions, and that dilution ultimately compressed the stock price. The process culminated in a 1-for-60 reverse stock split in February 2026, a move that was necessary to regain compliance with Nasdaq's US$1.00 minimum bid requirement. The stock declined 28.8% on the reverse split announcement alone, reflecting investor resentment toward years of dilution. The irony for the investors who sold is that their money ultimately helped reinvent the company into a very promising AI stock with a US$40 million run rate.

The question now is whether they closed that chapter of dilution. In March, the Board of Directors adopted a share repurchase plan of up to US$2.0 million worth of stock, subject to various conditions. They also announced a supplemental ATM just weeks later for US$39.0 million. Investors looking at this might be scratching their heads, asking why the company would buy stock back if it is going to dilute more. In a nutshell, the ATM is a tool to use for future acquisitions, and the share buyback will be executed if their cash flow supports it because they would be essentially buying the equity at such a severe discount. The moves together are a signaling mechanism that management is all about reducing the share count and is not interested in any more toxic financing using discounted convertible notes.

There are about US$1.67 million dollars of convertible notes left on the balance sheet. Should management use some of its cash to extinguish the note, it will go a long way in projecting confidence in the underlying business and the strength of its cash flow to fund its operational deficit.

Risks

There are a number of risks with HCTI's business plan. Integration is a risk because the company has to navigate different regulatory regions and different cultures while exercising employee oversight.

QuantumNexis must prove it can convert international partnerships into durable revenue, and Teyame/Datono must maintain execution while being folded into a public-company structure. There is also still financing risk because if margins fail to improve as expected or cash generation falls short, the company could again need to rely on the capital markets, reopening the dilution concerns that investors have not forgotten.

Near-Term Catalysts

There are some potential catalysts in the near term that may be inflection points. If the company begins its share repurchase plan or retires the convertible note, investors may get the hint that the era of dilution is truly over and may rerate the stock based on its future growth instead of its historic level of dilution. The road to profitability is not without risk. There's a big integration risk, but the company does have a buffer of cash to aid in the transition.

Management's plan includes dividends to shareholders from spin-offs, assuming they can successfully integrate their subsidiaries. The management team seems very capable and comfortable integrating companies and creating the accretion needed to propel the value of the holding company higher.

Investment Summary

Healthcare Triangle has undergone a dramatic transformation, and investors can't get the fear of dilution out of their heads to see the AI transformation that has taken shape. The low-margin legacy IT business was a means to an end. They can now leverage their 100 - 150 client relationships into meaningful recurring SaaS and agentic AI revenue.

The new acquisitions offer fantastic cross-selling opportunities and synergies. This year's revenue target of US$55.0 million and US$5.0 million in EBITDA means the company is extremely undervalued, considering it is trading at 1X cash. The fully diluted book value is ~US$19–20/share (7.7x the current market price). The most recent quarter demonstrated positive moves toward profitability, but the market remains in a "show me" state of mind and likely wants to see further evidence of profitability in the coming quarter before bidding up the stock.

Important Disclosures:

Mike Sheikh: I, or members of my immediate household or family, own securities of: None. My company has a financial relationship with: None. My company has purchased stocks mentioned in this article for my management clients: None. I determined which companies would be included in this article based on my research and understanding of the sector.
Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports was not paid by the author to publish or syndicate this article. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

( Companies Mentioned: HCTI:NASDAQ, )

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses

Fri, 05 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/05/2026

Rakovina Therapeutics (TSX.V: RKV) reported lower net losses, reduced administrative spending, debt restructuring, financing activity, and progress across its AI-driven oncology pipeline in Q1 2026.

Rakovina Therapeutics Inc. (RKV:TSX.V) reported its financial results for the three months ended March 31, 2026, and provided an update on recent corporate developments.

The company reported research and development expenses of CA$1,031,556 for Q1 2026, compared to CA$885,594 in Q1 2025. According to the company, the increase reflected expanded chemistry, artificial intelligence research, and contract research activity supporting the advancement of its AI-powered oncology pipeline.

General and administrative expenses were CA$443,986 in Q1 2026, down from CA$1,224,752 in the same period of 2025. The company said the reduction reflected cost management across consulting, investor relations, and compliance expenditures.

Research and development expenses represented approximately 70% of total operating expenses during the quarter, compared with 56% for the year ended Dec. 31, 2025. Cash and cash equivalents totaled CA$585,908 as of March 31, 2026, compared with CA$298,758 at Dec. 31, 2025. The company attributed the increase primarily to a CA$1.0 million convertible debenture financing completed on March 5, 2026.

Rakovina reported a working capital deficit of CA$729,019 at March 31, 2026, compared with CA$2,149,223 at Dec. 31, 2025. The company said the improvement followed refinancing and the extension of debt maturities into 2028 and 2029. Net loss for the quarter was CA$1,675,400, compared with a net loss of CA$2,179,823 in Q1 2025.

"Q1 2026 reflects the operating discipline we committed to earlier this year as we implemented the first phase of a restructuring for success," Chief Executive Officer Kim Oishi said in a company news release. "We reduced G&A by more than 60% year-over-year while maintaining R&D investment, as we transition into a focused, science-first drug discovery company."

The company also reported several corporate developments during the quarter and subsequent period. On April 22, 2026, Rakovina presented two preclinical posters at the American Association for Cancer Research Annual Meeting. The presentations highlighted data from its kt-5000 series dual ATR-mTOR inhibitor program and formulation work for kt-3283-LNP, a dual PARP/HDAC inhibitor being developed with Saudi partner, NanoPalm.

On March 5, 2026, the company completed a CA$1.0 million convertible debenture unit private placement and settled CA$1.59 million of its May 2023 convertible debentures. On March 12, 2026, Rakovina announced a non-brokered private placement of up to CA$1.0 million through the issuance of common shares at CA$0.12 per share, which was subsequently extended to April 9, 2026.

The company also noted that a previously announced January 2026 share offering of up to 5,000,000 common shares at CA$0.12 per share for gross proceeds of up to CA$600,000 did not close and has lapsed in accordance with its terms. Rakovina said it intends to formally withdraw the related submission from the TSX Venture Exchange.

Precision Oncology Continues to Drive Drug Discovery Innovation

According to a May 12 report from Research and Markets, the global targeted cancer therapy market was expected to expand from US$16.82 billion in 2025 to US$26.26 billion by 2031, reflecting a compound annual growth rate of 7.71%. The report said the market offered opportunities driven by "rising cancer rates, breakthroughs in genomics, and the need for personalized treatments," while also noting challenges tied to high development costs and strict regulations. It described targeted cancer therapy as a medical strategy focused on "identifying and exclusively targeting cancer cells by leveraging their unique molecular traits," with the goal of reducing collateral damage to healthy tissues.

Research and Markets also cited artificial intelligence as a developing trend in targeted cancer therapy. The report said, "The incorporation of artificial intelligence is transforming the targeted cancer therapy sector by speeding up the creation of diagnostics and the discovery of new drugs." It said AI systems could evaluate proteomic and genomic datasets, identify therapeutic targets, and forecast patient reactions with heightened accuracy. The report also said the market had been shaped by next-generation targeted treatments, including novel conjugate platforms, gene therapies, and complex cell therapies intended to address treatment resistance and unmet needs.

Fortune Business Insights reported on May 18 that the market had been driven by a substantial cancer patient burden and breakthrough product launches. It also noted that treatment initiation had increasingly moved into earlier stages of cancer because of diagnostic innovations such as biomarker testing.

According to Fortune Business Insights, targeted therapy and innovative delivery methods have been among the key trends in oncology drugs. The report said the market was "transitioning from the treatment of only metastatic disease to treating the earlier stages of the disease where cure is probable." It also said advanced subcutaneous formulations had been developed to improve infusion center throughput, reduce nursing time, and improve the patient experience. The report noted that combination therapies, including immunotherapy used with targeted therapies, had represented an area of market opportunity because mechanistically complementary drugs could improve depth and durability of response.

Drug Discovery Trends wrote on May 27 that biotech activity had strengthened, while oncology continued to draw a large share of investment. The report said oncology accounted for more than a quarter of biotech venture investment by deal value, at roughly 32%, up from 23% in 2020. Dr. Christiana Bardon, Managing Partner of MPM BioImpact, said, "It really wasn't until Q4 of last year that we started to see a rebound." She added, "I'm hoping we're seeing the return of the generalist investor to the biotech sector."

The May 27 report also described oncology development beyond established immunotherapy approaches, including RAS inhibitors, bispecific antibodies, and cell therapy delivery methods. Bardon said of pancreatic cancer research, "We've never had a breakthrough before in pancreatic cancer; all we've had is mostly failure and very incremental contributions." Discussing in vivo cell therapy approaches, she said, "This is utterly transformative because it would be off-the-shelf and could be used by community physicians."

Pipeline and Corporate Development Activities

Rakovina reported ongoing activity across several drug development programs and corporate initiatives. On January 8, 2026, the company announced an expansion of its collaboration with Variational AI focused on continued optimization of the kt-5000 series ATR-mTOR inhibitors. On January 27, 2026, Rakovina announced up to CA$1.5 million in new financing, debt restructuring, the appointment of Kim Oishi as chief executive officer, and the addition of Frank Holler to its board of directors.

At the AACR Annual Meeting in April 2026, the company presented preclinical data from its kt-5000 series program, which it said demonstrated anti-tumor activity, metabolic stability, selectivity, measurable central nervous system penetration, and tumor growth inhibition with improved tolerability relative to reference ATR inhibitors. The company also presented initial formulation data for kt-3283, showing development of a lipid nanoparticle formulation to support continued preclinical evaluation.

According to the company's May 2026 investor presentation, the kt-5000 program remains in lead optimization and is focused on dual ATR-mTOR inhibition for solid tumors, PTEN-deficient cancers, and central nervous system metastases. The company reported that 138 molecules had been predicted, 43 synthesized, and lead compounds confirmed as potent and selective, with central nervous system penetration and tolerability confirmed in vivo. The company also noted ongoing lead optimization through its expanded collaboration with Variational AI.

Rakovina also outlined progress in its kt-3000 dual PARP/HDAC inhibitor program. The company reported that kt-3283 demonstrated superior cytotoxicity compared with the FDA-approved drugs olaparib and vorinostat and that findings had been published in Clinical Cancer Research. The program is being advanced through a joint venture with NanoPalm involving lipid nanoparticle delivery technology, with Rakovina retaining intellectual property rights. [OWNERSHIP_CHART-11193]

The company's kt-2000 AI program remains focused on PARP inhibitors for breast, ovarian, and prostate cancers. Rakovina reported that billions of compounds were screened through its Deep Docking platform, with 389 compounds assessed against PARP and lead compounds confirmed with PARP selectivity and drug-like properties.

Ownership and Share Structure¹

Edison Oncology holds approximately 9.9% of Rakovina Therapeutics. Management and reporting insiders account for about 4% ownership, with the remainder held by a combination of institutional, retail, and other investors, as previously disclosed in company materials.

Rakovina completed a 10-to-1 share consolidation in June 2025, with shareholders receiving one post-consolidation common share for every ten previously held.

As of June 2026, Rakovina Therapeutics had approximately 24.4 million issued and outstanding shares.

Based on recent trading prices, the company's market capitalization was approximately CA$2.3 million to CA$3.0 million. in a range of approximately CA$0.09 to CA$0.84. and avoids giving a broad market-cap range.

[SMNLINSERT]

Important Disclosures:

Rakovina Therapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rakovina Therapeutics Inc.
James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RKV:TSX.V, )

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%

Thu, 04 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/04/2026

Revolution Medicines Inc.'s (RVMD:NASDAQ) daraxonrasib treats pancreatic cancer patients, doubling median survival. Analysts rate it a "Buy" with targets up to US$263.

On May 31, 2026, Revolution Medicines Inc. (RVMD:NASDAQ) announced detailed results from its global, randomized Phase 3 RASolute 302 clinical trial that evaluated daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). This potential new oncology drug is an oral RAS(ON) multi-selective inhibitor intended as a therapy for RAS-addicted cancers.

RAS is a key growth control switch in human cells and is the primary oncogenic driver of PDAC, which is typically characterized by excessive RAS(ON) signaling in tumors with or without a mutant allele of RAS. Daraxonrasib is the first investigational agent in its class of RAS(ON) multi-selective inhibitors. The randomized Phase 3 trial tested once-daily oral daraxonrasib and found "unprecedented improvements in overall survival and progression-free survival rates compared to standard therapies," according to the press release. The company reported that all primary and key secondary endpoints of the trial were met, while the drug exhibited a manageable safety profile and significantly delayed deterioration in cancer-related pain and overall quality of life compared to those treated with standard chemotherapy.

Mark A. Goldsmith, M.D., Ph.D., and CEO and Chairman of Revolution, said, "The data from the Phase 3 RASolute 302 trial clearly validate our pioneering, science-driven approach and add to the growing body of evidence underscoring the broad potential of RAS(ON) inhibition that we are testing across pancreatic cancer and other RAS-driven cancers." Dr. Goldsmith continued, "Daraxonrasib significantly elevates the survival bar in the treatment of one of the deadliest human cancers, while better preserving quality of life compared to chemotherapy. In this trial, daraxonrasib redefined treatment expectations in previously treated metastatic pancreatic cancer by reducing the risk of death by 60% and increasing median overall survival to more than one year, a result not previously reported in any Phase 3 clinical trial in any line of therapy for this disease. These striking results firmly support daraxonrasib as the new standard of care for patients with previously treated metastatic pancreatic cancer, and usher in a new era of RAS-targeted therapy for patients living with this disease."

Brian M. Wolpin, M.D., M.P.H., director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, professor of medicine at Harvard Medical School, and principal investigator for the RASolute 302 trial, also weighed in. Dr. Wolpin said, "These results from the Phase 3 RASolute 302 trial of daraxonrasib represent a major milestone for patients facing metastatic pancreatic cancer. For many patients, second-line chemotherapy provides modest benefits, and new treatments delivering more durable tumor control have been urgently needed. In this global randomized trial, daraxonrasib, an oral RAS(ON) inhibitor, doubled median overall survival compared to standard of care chemotherapy for patients with previously treated metastatic pancreatic cancer. Importantly, this survival benefit was achieved with a generally manageable safety profile, highlighted by the low rate of treatment discontinuation due to treatment-related side effects."

With optimism, Dr. Wolpin anticipated future results, saying, "These results will change how scientists, clinicians, and patients think about treatment for pancreatic cancer, and support a new paradigm where RAS(ON) inhibition enters standard of care for patients with previously treated metastatic pancreatic adenocarcinoma."

Revolution is a late-stage oncology pharma testing company headquartered in Redwood City, California. Its flagship drug, daraxonrasib, is designed to target cancers driven by a broad range of common RAS genotypes, including PDAC, non-small cell lung cancer (NSCLC), and colorectal cancer. In addition to the RASolute 302 trial, daraxonrasib is being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC and metastatic RAS mutant NSCLC.

Oncology Sector Demand Growing

Company a "Favorite" Among Analysts

Robert Driscoll of Wedbush gave Streetwise Reports a quote on the company on June 1, 2026, saying: "I'd say we already knew from a press release that the overall survival data were positive, but the ASCO presentation confirmed clear, consistent efficacy across all patients, with no new safety signals — 'no holes in the data'. And we see significant momentum continuing for the drug as RVMD prepares to file for approval, with its access program already demonstrating robust demand."

Also on June 1, Equity Analyst Faisal Khurshid at Jeffries said, "With pot'l approval coming soon (we think July/Aug), RVMD remains one of our favorite names." Khurshid continued, " We think there may be a path for RVMD to get 1L on the label simultaneously w/ initial approval in 2L . . . co. did not outright dismiss this possibility, but emphasized scope of label ultimately up to FDA."

Jeffries gave Revolution a "Buy" rating, with a US$185 price target.

LifeSci Capital's Charles Zhu, Ph.D., was even more optimistic in his June 1 research report, giving the company an "Outperform" rating, with a price target of US$263.00. Dr. Zhu said, " The results were universally positive, and the enthusiasm surrounding RASolute 302 was clear."

As a note, Robert Langreth for Bloomberg pointed out one specific concern with the data on May 31, 2026, writing: "Median duration of treatment was 6.2 months, but we think this could be longer in real-world practice. RASolute 302 did not allow treatment beyond PD, although it is formally allowed in subsequent protocols, and physician feedback has consistently reflected an openness to treating beyond progression. Thus, we expect the real-world duration of treatment to be longer than reported here." [OWNERSHIP_CHART-11622]

Sean McCutcheon, Ph.D., of Raymond James gave the company a "Strong Buy" rating on May 31, 2026, noting that "the progression-free survival results were strong" and arguing that "overall survival rates are a home run and are consistent across all prespecified subgroups."

A Pipeline Moving Fast

The company's investor presentation shows that Revolution has no plans to let these results stagnate and has already laid out the next steps. First, the company intends to provide eligible patients with this treatment option as soon as possible, with FDA-cleared Earl Access Program operations accessible to U.S.-licensed physicians on behalf of eligible patients. Next, the company is advancing multiple components of NDA through rolling submissions and sequential filings planned for international regulatory authorities.

With core operations and networks established in the U.S., Revolution is launching its representative team to access priority international markets across a range of oncology builds and launches.

Ownership & Share Information¹

Revolution Medicines Inc. has a market cap of US$34.80 billion, with 212.60 million shares outstanding. The company's 52-week range is US$34.00-US$266.50.

Institutions own 95.35% of shares, while Management & Insiders own 1.89%. The remaining 2.76% of shares are held by Retail.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: RVMD:NASDAQ, )

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug

Mon, 01 Jun 2026 00:00:00 PST

Source: Streetwise Reports 06/01/2026

Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.

On May 12, 2026, Capricor Therapeutics Inc. (CAPR:NASDAQ) announced financial results for Q1 2026 and provided significant corporate updates. Capricor is a pre-commercial biotech company focused on developing "transformative cell and exosome-based therapeutics for the treatment of rare diseases. Specifically, the company is currently developing Dermiocel (CAP-1002), a drug intended to treat Duchenne Muscular Dystrophy (DMD).

DMD is a severe, X-linked genetic disorder characterized by worsening muscle degeneration that affects the skeletal, respiratory, and cardiac muscles. According to the company, "It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain limited."

The company's flagship drug, Dermiocel, consists of allogeneic cardiosphere-derived cells (CDCs), which are a rare population of cardiac cells that have shown potent immunomodulatory and anti-fibrotic actions during clinical and preclinical studies. CDCs excrete exosomes, which target macrophages and alter their expression profile to adopt a healing phenotype.

So far, Deramiocel has received Orphan Drug Designation for the treatment of DMD from both the U.S. FDA and the European Medicines Agency (EMA). In addition, it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S., Advanced Therapy Medicinal Product (ATMP) designation in Europe, and Rare Pediatric Disease Designation from the FDA.

Capricor's Q1 financial highlights include:

Cash Position: Cash, cash equivalents, and marketable securities totaled approximately US$278.6 million as of March 31, 2026, compared to approximately US$318.1 million as of December 31, 2025.
Revenues: There was no revenue recognized for the first quarter of 2026 or 2025.
Costs and Expenses: Total operating expenses for Q1 2026 were approximately US$36.8 million, compared to approximately US$25.0 million for Q1 2025.
Net Loss: The company reported a net loss of approximately US$33.9 million, or US$0.59 per share, for Q1 2026, compared to a net loss of approximately US$24.4 million, or US$0.53 per share, for Q1 2025.
Financial Outlook: The company believes that, based on the current operating plan and financial resources, its available cash, cash equivalents, and marketable securities will be sufficient to cover anticipated expenses and capital requirements through Q4 2027. This outlook excludes any potential revenue from product sales, the potential monetization of a PRV, if received, or other non-operating sources of capital.

Capricor has packed the first quarter of 2026 with numerous operational highlights. Some include:

Capricor's Biologics License Application (BLA) for Deramiocel is currently under review by the U.S. Food and Drug Administration.
Cardiac MRI analyses showed a significant reduction in myocardial fibrosis by late gadolinium enhancement (LGE) versus placebo, a clinically meaningful finding given that fibrosis is cumulative and irreversible. The Duchenne Video Assessment (DVA) "eat 10 bites" measure, a home-based, caregiver-captured assessment of upper limb function and daily living activities, demonstrated statistically significant improvement versus placebo, directly correlated with patient independence and quality of life.
The company's manufacturing facility in San Diego successfully completed an FDA Pre-License Inspection. The facility is operational and positioned to support initial commercial launch. Second-floor expansion is underway, with the goal of scaling to approximately 2,000–2,500 patients per year, roughly 10,000 doses annually, at full capacity.
Capricor has secured Michael Maurer as its Chief Commercial Officer (CCO) with direct DMD commercial experience.
Approximately 90 patients are currently enrolled across Capricor's collective open-label extension studies, with several patients receiving continuous intravenous infusions of Deramiocel for up to five years. Deramiocel has maintained a consistent, well-tolerated safety profile across more than 800 infusions.
Upon potential approval, Capricor expects to be eligible to receive a Rare Pediatric Disease Priority Review Voucher (PRV). PRVs are transferable and can be monetized through sale, representing a meaningful potential source of non-dilutive capital.

Linda Marbán, Ph.D., and CEO of Capricor, said in the release: "Capricor enters this pivotal moment with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy. With the FDA review of our BLA underway and a PDUFA target action date of August 22, 2026, our highest priority is execution: working closely with the agency, preparing for potential launch, and continuing to build the capabilities of a commercial-stage company. We remain focused on ensuring that Deramiocel reaches every eligible patient as quickly as possible…"

"Our thesis is straightforward: a potential first-in-class approval in a defined rare disease population, proprietary in-house manufacturing, a growing pipeline, and a leadership team with the conviction and the capital to execute," continued Dr. Marbán. "We are building something that will create meaningful and durable value for patients, for this company, and for the shareholders who have believed in this mission."

Biotech Sector Demands Funding

At the same time, J. Edward Moreno of Sherwood News reported contradictory news on January 14, 2026, writing that, "In 2025, announced global biotech deals totaled US$228.4 billion, up from US$132.3 billion in 2024, data from Dealogic shows . . . Just two weeks into 2026, US$9.2 billion in deals have been announced."

According to Moreno, movement is expected in the sector: "As some of the most lucrative drugs lose exclusivity in the next few years, pharmaceutical giants are increasingly shopping around for biotechs to add to their portfolios — and they are more than happy to pay a hefty premium for the right company . . . For some Big Pharma companies, business development spending is now about equal to, or more than, research and development."

This statement could explain the emerging drop in research and development spending at biotech and pharma companies. On March 25, 2026, BioSpace's Annalee Armstrong reported that, "R&D spending at the top 16 pharmaceutical companies declined by 3.6% overall in 2025, as many aggressively cut spending and refocused pipelines."

"Buy" Ratings All Around

Several analysts issued or reiterated ratings and target prices after Capricor announced its Q1 2026 financials. For Oppenheimer, Leland Gershell, MD, Ph.D., gave the company an "Outperform" rating, with a 12-18-month price target of US$54.00 on May 12, 2026. Gershell wrote, "Following recent Phase 3 success for lead candidate Deramiocel in Duchenne Muscular Dystrophy (DMD), we anticipate FDA approval in 3Q. We forecast ~US$1.1B in 2031 sales by commercial partner NS Pharma, of which we model ~US$315M net share to CAPR that year. We believe Deramiocel's growing revenue stream will support advancement of the company's preclinical exosome technology, a cell-free platform with broad therapeutic and vaccine potential that could generate lucrative industry deals over time." [OWNERSHIP_CHART-6659]

The following day, on May 13, 2026, Joseph Pantiginis, Ph.D., gave the company a "Buy" rating for H.C. Wainwright & Co. With a price target of US$60, Pantiginis said, "Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, Deramiocel, in DMD patients. There is no contribution from added Deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation."

Finally, Boobalan Pachaiyappan, Ph.D., managing director and senior research analyst for Roth, weighed in after Capricor announced Mr. Maurer's addition to the team. He wrote, " We have assessed Capricor Therapeutics using a discounted cash flow (DCF) methodology by employing an 85% POA, 9% discount rate, and a 0% terminal growth rate, yielding a market value of US$2.07 million. Our estimates suggest that Deramiocel could be launched in the U.S. in 2027, with potential loss of exclusivity beginning in 2039."

A Multi-Drug Pipeline

Capricor awaits full facility validation, with FDA approval targeted for the first half of 2027.

The company's StealthX™ platform is advancing several therapeutic programs, with a focus on muscle-targeted delivery of siRNA, proteins, and small molecules. Capricor is also laying the groundwork for the expansion of Deramiocel into Becker muscular dystrophy and engaging regulatory authorities in Europe and Japan.

Ownership & Share Information¹

Capricor Therapeutics Inc. has a market cap of US$1.74 billion, with 57.91 million shares outstanding. The company's 52-week range is US$4.30-US$40.37.

Institutions own 59.72% of shares, while Strategic Investors own 8.54%. Management & Insiders own 0.94% of shares, and the remaining 30.8% of shares are held by Retail.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: CAPR:NASDAQ, )

Biopharma Company Reveals High-Impact SCI Recovery Gains

Thu, 28 May 2026 00:00:00 PST

Source: Streetwise Reports 05/28/2026

NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.

NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) announced on May 26, 2026, the results of positive independent, blinded biomechanical gait analyses demonstrating neural recovery with its drug, NVG-291, in the Phase 1b/2a CONNECT SCI study. Newton Tech, an AI-powered movement intelligence company specializing in video-based motion capture and computational analysis of standardized walking assessments to produce quantitative measures of gait quality, analyzed the biomechanical data.

Based on the Global Statistical Test, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the hallmarks of genuine neural recovery, versus 10% of placebo subjects. The data analyzed coordination, mechanical effort, and postural stability.

Key findings from the analyses include:

Multivariate Global Treatment Effect (GTE): Integrating the established hallmarks of genuine neural recovery into a unified assessment, the GST demonstrated a statistically significant treatment effect favoring NVG-291 (GTE = +0.45; 95% CI: +0.15 to +0.72; p=0.0197), corresponding to a 72.7% probability of treatment benefit with NVG-291 versus placebo.
Responder Analysis: Based on the GST, 100% (10/10) of NVG-291 subjects were classified as responders across the composite of the recovery measures of coordination, mechanical effort, and postural stability, compared to just 10% (1/10) of placebo subjects (p=0.0001). A responder was classified as a subject who outperformed the majority of opposite-arm subjects across the composite.
Speed-Effort Dissociation: Among placebo subjects, gains in walking speed were statistically correlated with increased mechanical effort (peak knee angular velocity vs. speed: r=+0.83; p=0.003), consistent with compensation. This association was not observed in NVG-291 subjects, consistent with speed gains driven by restored neural control rather than compensatory effort.
Consistency Across Recovery Measures: The multivariate treatment effect was consistent across all three recovery measures, with each favoring NVG-291 with statistical significance versus placebo.

Adam Rogers, MD, President, and CEO of NervGen, said in the release, "These results extend the robust efficacy observed in the Phase 1b/2a CONNECT SCI study, providing independent and objective evidence that NVG-291 is promoting genuine neural recovery, as reflected in lower-body locomotor function. In a chronic population, where meaningful natural recovery has largely plateaued, these findings strengthen the growing evidence supporting NVG-291 as a potentially best-in-class restorative therapy for chronic tetraplegia. When combined with previously reported clinical improvements, these new biomechanical findings further reinforce the foundation upon which we are advancing NVG-291 into the Phase 3 RESTORE registrational study in chronic tetraplegia, and our potential path to approval as the first pharmacologic therapy capable of enabling the nervous system to repair itself."

NervGen Pharma Corp. is a Canadian clinical-stage biopharmaceutical company focused on developing the first neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions.

Pharma Sector R&D Spending Unstable but Crucial

Neurorestorative therapies aim to repair and regenerate neural tissue after traumatic injuries, enacting ". . . a shift from simply protecting the brain to actively helping it heal."

Anticipated Data "As Good As We Hoped"

Scott McAuley, Ph.D., provided an April 15, 2026, research note for Paradigm Capital and gave the company a "Speculative Buy" rating, with a price target of CA$4.32. McAuley expressed anticipation for the results of the Phase 2 RESTORE trial, stating, "We conservatively assume that top-line data will be released in mid-2028, with approval in 2030."

Andre Uddin, Ph.D., and Seungwoo Lee, Ph.D., also provided opinions on NervGen on April 27, 2026. The pair rated the company a "Speculative Buy", with a price target of CA$5.50. The addition of Dr. Keith Vendola to the management team as CFO seemed to be their main driver. They wrote, "In our view, adding a CFO with deep corporate finance and capital markets experience strengthens the management team ahead of important milestones."

H.C. Wainwright and Co.'s Raghuram Selvaraju, Ph.D., weighed in on April 27, 2026, as well. Selvaraju gave the company a "Buy" rating, with a price target of CA$18.00. "We believe that NVG-291 could be launched independently, even by a company of NervGen's size. The unmet nature of the medical need in chronic SCI patients may permit ultra-premium pricing, but even pricing in the US$200K range would imply peak sales potential exceeding US$2B at only a ~10% market penetration rate," he wrote, arguing that the current patient population is "almost totally unserved."

On May 26, 2026, Chen Lin of What is Chen Buying? What is Chen Selling? wrote: "Last Friday was a very bad day for NGEN. NGEN is listed on Nasdaq, and shares hit seven. I thought they would raise at that time, just like MSLE, but they didn't. They were taunting the Gait data. I thought it would be a good one, and the stock would pop, then they would raise the money. But they raised money last week — US$60 million at 2.5 with a 5-year warrant at 3.68, which is a huge dilution of existing shareholders. This kind of raise happened often in the bear market three years ago, which I was trying hard to avoid, but it is very hard to accept now as biotech is in a much better environment."

Lin continued: "This morning, the long-awaited Gait data came out, and it was as good as we hoped — 10 out of 10 showed improvement vs 1 out of 10 in placebo groups. I do think they have a chance for accelerated approval (AA). If NGEN files for AA in the coming week, with the financing overhang, it is probably a good buying opportunity. If they don't file, it would be a 2028 story." [OWNERSHIP_CHART-10026]

Phase 3 Plans in Place

The company plans to begin the RESTORE Phase 3 registrational study in mid-2026. Design and guidelines for Phase 3 will be as follows:

Study Design: Randomized, double-blind, placebo-controlled; approximately 150 subjects.
Population Characteristics: Adults aged 18-75 with chronic tetraplegia due to traumatic SCI (≥C7; ASIA Impairment Scale C or D), 1-10 years post-injury.
Study Sites: Up to 60 sites across the United States and Canada.
Dosing Regimen: Daily subcutaneous injections of NVG-291 for 12 weeks, followed by a 4-week observational period.
Primary Endpoint: Change from baseline to Week 12 in GRASSP Quantitative Prehension (QtP), a validated measure of functional hand use.
Key Secondary Endpoints: PGIC, CGIC, Spinal Cord Independence Measure, Version-III (SCIM-III), and lower extremity spasticity, as measured by the Modified Ashworth Scale.
Qualitative Assessments: Blinded qualitative interviews will be conducted when exiting the 16-week study period to contextualize the clinical meaningfulness and real-world impact of NVG-291.
Open-Label Extension (OLE): An optional 12-week OLE will follow the main study, providing access to NVG-291 for all placebo-randomized subjects.

Ownership & Share Information¹

NervGen Pharma Corp. has a market cap of US$175.07 million, with 82.19 million shares outstanding. The company's 52-week range is US$1.50-US$6.30.

Institutions own 0.18% of shares, while Management & Insiders own 2.51%. Strategic Investors own 18.42%, and the remaining shares are held by Retail.

Important Disclosures:

Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

( Companies Mentioned: NGEN:TSX.V; NGENF:OTCQX, )

The Life Sciences Report

Biopharma Co. Trials Precision Medicine Breakthrough for Dry Eye Disease. Gets Positive Results

Pharma Sector R&D Underfunded

Stock Earns "Buy" Rating

Phase 3 Trials Imminent

Ownership & Share Structure1

MindBio Therapeutics Advances AI Voice Tech for Workplace Safety in Growing Biotech and AI Detector Markets

Market Opportunity in Safety and Detection Technologies

Prototype Delivery Marks Key Milestone

Addressing Risks Across High-Stakes Industries

Strategic Partnerships and Expansion Plans

Analyst Perspectives and Valuation Considerations

Share Structure and Ownership Profile

MindBio Therapeutics Positions Voice AI Kiosks for Growth in Workplace Safety Markets

Why MindBio Therapeutics Stands Out in Voice Biomarker Development

Unique Business Model Focused on Scalable, Non-Invasive Screening

Key Catalysts Include Prototype Delivery and Sector Partnerships

Industry Timing Aligns With Rising Safety and Regulatory Pressures

Analyst Perspectives and Valuation Context

Share Structure and Ownership Overview

MindBio Therapeutics Positions Voice AI Technology for Growth in Safety-Critical Sectors

Market Opportunity in AI-Driven Detection

Why MindBio Stands Out with Its Core Technology

Unique Business Model and Competitive Edge

Key Catalysts and Deployment Timeline

Industry Timing and Supporting Trends

Analyst Perspectives and Valuation Context

Share Structure and Ownership Details

Grey Matters Health Positions for Growth in Expanding Alzheimer's Diagnostics Market

Biotech Firm Launches Massive AI Safety Solution for Zero-Tolerance Industries

Better Detection Needed in Zero-Tolerance Industries

Experts Anticipate First-of-Its-Kind Tech

Multiple Industries Targeted

Ownership & Share Information2

ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market

Market Tailwinds Support Innovation

Analyst Sentiment and Upcoming Milestones

Alzheimer's Diagnostic Clinic Initiative Moves Forward After Financing Close

Early Detection and AI Reshape Alzheimer's Imaging

Analyst Discussed Alzheimer's Diagnostic Clinic Strategy

Neuroimaging Clinic Development Plans

Ownership and Share Structure2

Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth

Cancer Research Needs Grow

Analysts Look Forward to Next Results

Two Drugs in the Pipeline

Ownership & Share Information1

Biotech Firm Deploys Revolutionary Intox AI, Unlocking Billion-Dollar Industrial Safety Opportunity

Intoxication Detection Methods Needed

Experts See MindBio as Problem-Solver

Tackling New Issues

Ownership & Share Information2

From Healthcare IT Vendor to AI-Driven Holding Company

Three-Business Structure

Purpose Health

QuantumNexis

Teyame/Datono Acquisition

Financial Review

Capital Structure Reset

Risks

Near-Term Catalysts

Investment Summary

Cancer Drug Developer Shifts 70% of Spending to Research as AI Pipeline Progresses

Precision Oncology Continues to Drive Drug Discovery Innovation

Pipeline and Corporate Development Activities

Ownership and Share Structure1

California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60%

Oncology Sector Demand Growing

Company a "Favorite" Among Analysts

A Pipeline Moving Fast

Ownership & Share Information1

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug

Biotech Sector Demands Funding

"Buy" Ratings All Around

A Multi-Drug Pipeline

Ownership & Share Information1

Biopharma Company Reveals High-Impact SCI Recovery Gains

Pharma Sector R&D Spending Unstable but Crucial

Anticipated Data "As Good As We Hoped"

Phase 3 Plans in Place

Ownership & Share Structure¹

Ownership & Share Information²

Ownership and Share Structure²

Ownership & Share Information¹

Ownership & Share Information²

Ownership and Share Structure¹

Ownership & Share Information¹

Ownership & Share Information¹

Ownership & Share Information¹